Results 101 to 110 of about 71,560 (137)

Glucagon-like Peptide-1 Receptor Agonists and Ocular Disease: Mechanisms, Evidence and Therapeutic Perspectives. [PDF]

Int J Mol Sci
Gong X, Örge FH.
europepmc   +1 more source

Glucagon-like peptide-1 analogs reduce alcohol intake

Endocrine Abstracts
Maurice O'Farrell, Faisal I. Almohaileb, Carel W. le Roux   +2 more
openaire   +2 more sources

Consumer Food Purchases After Glucagon-Like Peptide-1 Receptor Agonist Initiation.

JAMA Netw Open
Sørensen KK, Møller FT, Yazdanfard PDW, Hasselbalch R, Kragholm KH, Andersen MP, Torp-Pedersen C.   +6 more
europepmc   +1 more source

Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits. [PDF]

J Clin Invest
Wong CK, Drucker DJ.
europepmc   +1 more source

The Beneficial Effects of Glucagon-Like Peptide-1 Agonists on Blood Pressure: A Comprehensive Review. [PDF]

Rev Cardiovasc Med
Gala D, Botros F, Makaryus AN.
europepmc   +1 more source

Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review. [PDF]

Ther Adv Psychopharmacol
Lee S, Yin L, Teopiz KM, Wong S, Han Le G, Xiao N, Stahl S, Valentino K, Ho R, Zhang MC, Greg Rhee T, McIntyre RS.   +11 more
europepmc   +1 more source

Delayed-Onset Amiodarone Induced Thyrotoxicosis After Glucagon-Like Peptide-1 Agonist-Related Weight Loss. [PDF]

JCEM Case Rep
Black ML, Coyle CG, Bernet VJ, McLeod CJ, Chindris AM.   +4 more
europepmc   +1 more source

The Impact of Glucagon-Like Peptide-1 (GLP-1) Agonists on Acne, Hidradenitis, and Sebaceous Activity. [PDF]

Cureus
Jabin A, Khan S, Khan H, Durrani ZU, Hamza K, Gul F, Atta Ullah S, Dayam F, Yaseen M, Shah S.   +9 more
europepmc   +1 more source